NCT03175731

PPIs and Gastroesophageal Varices in Liver Cirrhosis (PPIs: Proton Pump Inhibitors)

A Randomized Controlled Study on the Effects of PPIs on Gastroesophageal Variceal Bleeding in Liver Cirrhosis (PPIs: Proton Pump Inhibitors)

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 106 (actual)
• Sponsor: Yanjing Gao · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is aimed at investigating the effect of PPIs on gastroesophageal varices in liver cirrhosis. Half of participants will receive PPI, while the other half will receive a placebo.

Detailed description

PPIs can inhibit parietal cell H+/K+-ATPase and reduce secretion of gastric acid. PPIs can promote platelet aggregation and stabilize the formation of fibrin thrombosis by maintaining the high pH environment in the stomach and inactivating pepsin. The effect of PPIs on ulcerative upper gastrointestinal bleeding was confirmed but it is not clear whether PPIs is applicable in esophagogastric variceal bleeding whose etiology and bleeding position are different from ulcerative upper gastrointestinal bleeding. There is lack of consensus and sufficient evidences to support to use PPIs in esophagogastric variceal bleeding in cirrhotic patients universally. Nevertheless, the use of PPIs in liver cirrhotic patients with gastroesophageal varices is common.

Conditions

• Liver Cirrhosis
• Hypertension, Portal

Interventions

Type	Name	Description
DRUG	Proton Pump Inhibitors	Pantoprazole 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.
DRUG	Placebo	Placebo 40mg per day intravenously or orally for 2 weeks after endoscopic treatment.

Timeline

• Start date: 2017-05-01
• Primary completion: 2019-08-30
• Completion: 2019-08-30
• First posted: 2017-06-05
• Last updated: 2021-06-09
• Results posted: 2021-06-09

Locations

1 site across 1 country: China